Semaglutide has been approved for reducing the risk of major adverse cardiovascular events in patients with obesity and heart disease, as well as for preventing the progression of kidney disease in individuals with type 2 diabetes and chronic kidney disease
Dosing Strategies for Weight Loss Weight Loss Results with Retatrutide Phase 2 trial results by dose: 1mg produced 8.7% weight loss, 4mg hit 17.3%, 8mg reached 22.8%, and the 12mg group lost 24.2% at 48 weeks
We anticipate a significant difference in peri- and postoperative complications in patients with severe diabetes and disease sequelae, before and following the implementation of the ASA GLP-1 guidelines to hold GLP-1RA therapy prior to procedures requiring general anesthesia
Eli Lilly, the pharmaceutical company developing retatrutide, has progressed the compound into Phase 3 clinical trials, which are evaluating its efficacy and safety in larger populations across multiple indications, including obesity and type 2 diabetes
